Neuro-ophthalmic adverse events associated with COVID-19 … – Modern Retina

Image credit: bizoo_n stock.adobe.com

Korean researchers reported that ptosis was associated with COVID-19 vaccination, particularly with the ChAdOx1 vaccine (AstraZeneca), while Guillain-Barr syndrome/Miller Fisher syndrome was associated with the COVID-19 infection,1 according to first authors Jae Yong Han, MD, and Sunyeup Kim, MD, from, respectively, the Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea, and the Department of Medical AI, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

With the numbers of infected individuals and vaccine recipients are rising, a growing number of ocular adverse events, including neuro-ophthalmic adverse events, have been reported in individuals with the COVID-19 infection and vaccinated individuals.2-6 Other studies reported that COVID-19 was associated with optic neuritis7-9 and ophthalmoplegia was related to third or sixth cranial nerve palsy.10-16 Adverse events caused by the vaccine have been reported.1721 However, the investigators explained, it is unclear if COVID-19 infection and vaccination are related directly to neuro-ophthalmic adverse events.

They conducted a large nationwide, population-based, retrospective cohort study to determine if there is an association between COVID-19 infection and vaccination with neuro-ophthalmic adverse events.

About 8.5 million patients in the Korean National Health Claim Database were classified in 1 of 3 groups: controls, those with the COVID-19 infection, and those vaccinated against COVID-19. The researchers separately analyzed the early phase (within 60 days) and late phases (61180 days) to estimate the incidence rates and hazard ratio (HR) for each neuro-ophthalmic adverse event that included optic neuritis, papilledema, ischemic optic neuropathy, third nerve palsy, fourth nerve palsy, sixth nerve palsy, facial palsy, nystagmus, ptosis, blepharospasm, anomalies of pupillary function, and Guillain-Barr syndrome/Miller Fisher syndrome.

The authors reported that neuro-ophthalmic adverse events, except for ptosis and Guillain-Barr syndrome/Miller Fisher syndrome, showed no significant increase after COVID-19, and their incidence rates were extremely low. The incidence rates of ptosis in the early and late phases were significantly higher in patients who received the COVID-19 vaccination (HR = 1.65 in the early phase and 2.02 in the late phase) compared with the control group. The BNT162b2 (PfizerBioNTech) vaccine was associated with a lower ptosis risk than the ChAdOx1 vaccine. Guillain-Barr syndrome/Miller Fisher syndrome occurred significantly more often during the early phase (HR = 5.97) in patients with COVID-19 infection than in the control group.

The authors concluded, Ptosis was associated with the COVID-19 vaccination, particularly with the ChAdOx1 vaccine, while Guillain-Barr syndrome/Miller Fisher syndrome was associated with the COVID-19 infection. In contrast, no association was found between other neuro-ophthalmic adverse events and COVID-19 infection or vaccination. These results may provide helpful insights for diagnosing and treating neuro-ophthalmologic adverse events after COVID-19.

Originally posted here:

Neuro-ophthalmic adverse events associated with COVID-19 ... - Modern Retina